These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

584 related articles for article (PubMed ID: 30928481)

  • 1. IgE-Mediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy.
    Humbert M; Bousquet J; Bachert C; Palomares O; Pfister P; Kottakis I; Jaumont X; Thomsen SF; Papadopoulos NG
    J Allergy Clin Immunol Pract; 2019; 7(5):1418-1429. PubMed ID: 30928481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omalizumab: a future innovation for treatment of severe ocular allergy?
    Williams PB; Sheppard JD
    Expert Opin Biol Ther; 2005 Dec; 5(12):1603-9. PubMed ID: 16318424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of anti-IgE therapy beyond allergic asthma.
    Stokes JR; Casale TB
    J Allergy Clin Immunol Pract; 2015; 3(2):162-6. PubMed ID: 25609342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Efficacy of Omalizumab in Patients with Chronic Rhinosinusitis with Nasal Polyps and Comorbid Severe Allergic Asthma.
    Atayik E; Aytekin G; Aydin İ; Omeroglu E
    Iran J Allergy Asthma Immunol; 2024 May; 23(3):245-256. PubMed ID: 39422385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omalizumab, an anti-immunoglobulin E antibody: state of the art.
    Incorvaia C; Mauro M; Russello M; Formigoni C; Riario-Sforza GG; Ridolo E
    Drug Des Devel Ther; 2014; 8():197-207. PubMed ID: 24532966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-IgE monoclonal antibody (omalizumab) in the treatment of atopic asthma and allergic respiratory diseases.
    D'Amato G; Liccardi G; Noschese P; Salzillo A; D'Amato M; Cazzola M
    Curr Drug Targets Inflamm Allergy; 2004 Sep; 3(3):227-9. PubMed ID: 15379589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omalizumab versus intranasal steroids in the post-operative management of patients with allergic fungal rhinosinusitis.
    Mostafa BE; Fadel M; Mohammed MA; Hamdi TAH; Askoura AM
    Eur Arch Otorhinolaryngol; 2020 Jan; 277(1):121-128. PubMed ID: 31552526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omalizumab improves sinonasal outcomes in patients with chronic rhinosinusitis with nasal polyps regardless of allergic status.
    Gevaert P; Mullol J; Saenz R; Ko J; Steinke JW; Millette LA; Meltzer EO
    Ann Allergy Asthma Immunol; 2024 Mar; 132(3):355-362.e1. PubMed ID: 37951571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic Rhinosinusitis with Nasal Polyps: Targeting IgE with Anti-IgE Omalizumab Therapy.
    Kariyawasam HH; James LK
    Drug Des Devel Ther; 2020; 14():5483-5494. PubMed ID: 33328726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IgE-Related Chronic Diseases and Anti-IgE-Based Treatments.
    Navinés-Ferrer A; Serrano-Candelas E; Molina-Molina GJ; Martín M
    J Immunol Res; 2016; 2016():8163803. PubMed ID: 28097159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma.
    D'Amato G; Piccolo A; Salzillo A; Noschese P; D'Amato M; Liccardi G
    Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):225-31. PubMed ID: 19075985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis.
    Jat KR; Walia DK; Khairwa A
    Cochrane Database Syst Rev; 2015 Nov; (11):CD010288. PubMed ID: 26545165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of Dupilumab.
    Harb H; Chatila TA
    Clin Exp Allergy; 2020 Jan; 50(1):5-14. PubMed ID: 31505066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-immunoglobulin E in the treatment of refractory atopic dermatitis.
    Kim DH; Park KY; Kim BJ; Kim MN; Mun SK
    Clin Exp Dermatol; 2013 Jul; 38(5):496-500. PubMed ID: 23083013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A real world study of anti-IgE monoclonal antibody in the treatment of allergic united airway disease].
    Sui HJ; Zhen Z; Wang QG; Cong TC; Huang JJ; Hu Y
    Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Feb; 57(2):273-280. PubMed ID: 36797588
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical efficacy and immunologic effects of omalizumab in allergic bronchopulmonary aspergillosis.
    Voskamp AL; Gillman A; Symons K; Sandrini A; Rolland JM; O'Hehir RE; Douglass JA
    J Allergy Clin Immunol Pract; 2015; 3(2):192-9. PubMed ID: 25640470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Off-Label Uses of Omalizumab.
    El-Qutob D
    Clin Rev Allergy Immunol; 2016 Feb; 50(1):84-96. PubMed ID: 26048266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of dupilumab on atopic manifestations in patients treated for atopic dermatitis in real-life practice.
    Tauber M; Apoil PA; Richet C; Laurent J; De Bonnecaze G; Mouchon E; Cassagne M; Marguery MC; Hegazy S; Konstantinou MP; Severino M; Uthurriague C; Giordano-Labadie F; Didier A; Paul C
    Br J Dermatol; 2019 Jun; 180(6):1551-1552. PubMed ID: 30633329
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-term omalizumab efficacy in allergic rhinitis.
    Cavaliere C; Begvarfaj E; Incorvaia C; Sposato B; Brunori M; Ciofalo A; Greco A; de Vincentiis M; Masieri S
    Immunol Lett; 2020 Nov; 227():81-87. PubMed ID: 32798500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omalizumab in children with severe allergic disease: a case series.
    Crisafulli G; Caminiti L; Chiera F; Arasi S; Salzano G; Panasiti I; Barbalace A; Pajno GB
    Ital J Pediatr; 2019 Jan; 45(1):13. PubMed ID: 30642367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.